2012
DOI: 10.1038/nrgastro.2011.248
|View full text |Cite
|
Sign up to set email alerts
|

Advances in IBD management—towards a tailored approach

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 10 publications
0
6
0
Order By: Relevance
“…TRUC MLNs compositionally resembled deep colonic crypt communities (Pédron et al , 2012) with both being enriched in aerotolerant clades that are rare in stool (Figure 4e; Supplementary Figure S8). Based on evidence for a dominant presence of aerotolerant genera at the oxygen-rich mucosal surfaces of intestinal epithelial cells (Engel and Neurath, 2010; Marteyn et al , 2010; Pineton de Chambrun and Sandborn, 2012), our findings suggest that aerotolerant microbes may have greater access to the MLNs.…”
Section: Resultsmentioning
confidence: 72%
See 2 more Smart Citations
“…TRUC MLNs compositionally resembled deep colonic crypt communities (Pédron et al , 2012) with both being enriched in aerotolerant clades that are rare in stool (Figure 4e; Supplementary Figure S8). Based on evidence for a dominant presence of aerotolerant genera at the oxygen-rich mucosal surfaces of intestinal epithelial cells (Engel and Neurath, 2010; Marteyn et al , 2010; Pineton de Chambrun and Sandborn, 2012), our findings suggest that aerotolerant microbes may have greater access to the MLNs.…”
Section: Resultsmentioning
confidence: 72%
“…Use of immunomodulatories in IBD has increased given their longer disease-remission periods and fewer side effects as compared with corticosteroids (Yanai and Hanauer, 2011; Pineton de Chambrun and Sandborn, 2012). However, knowledge of the effects of specific immunomodulatories on gut microbiomes is limited (Engel and Neurath, 2010).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is deemed to arise from a dysregulated immune response to gut microbial communities in individuals with genetic predisposition ( Ott et al, 2004 ; Presley et al, 2012 ). Because the precise etiology of IBD still remains unknown, the management of IBD has mainly relied on palliative therapy with several non-specific agents for years, such as corticosteroids ( Engel and Neurath, 2010 ), antibiotics ( Dethlefsen et al, 2008 ), immunosuppressor ( Pineton de Chambrun and Sandborn, 2012 ), synbiotics ( Furrie et al, 2005 ), and agents aiming pro-inflammatory pathways. Nevertheless, many existing therapies are not effective for all patients and some even carry high-risk side effects or complications.…”
Section: Introductionmentioning
confidence: 99%
“…[6,7]) and IBDs (reviewed in refs. [8,9]). PGRN, also known as GRN-epithelin precursor [10], proepithelin [11,12], acrogranin [13], and GP88/PC cell-derived growth factor [14], is a 593-aa growth factor that is secreted from cells mediated by its signal peptide.…”
Section: Introductionmentioning
confidence: 99%